<div id="readability-page-1"><article>CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia. The complete list of Editas Medicine presentations is below. American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15 Oral Presentation: Title: Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C Session Date and Time: Thursday, May 14, 3:30 p.m. – 5:00 p.m. EDT Session Title: Gene Therapy for Cardiovascular Diseases Presentation Room: 206AB Final Abstract Number: 380 Poster Presentations: Title: Pharmacokinetics and Pharmacodynamics of In Vivo Gene Editing Therapy for Lowering LDL-C in Mice Session Date and Time: Thursday, May 14, 5:00 p.m. – 6:30 p.m. EDT Session Title: Thursday Poster Reception Presentation Room: Exhibit and Poster Hall Final Abstract Number: 3423 Title: In Vivo CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model Session Date and Time: Wednesday, May 13, 5:00 p.m. – 6:30 p.m. EDT Session Title: Wednesday Poster Reception Presentation Room: Exhibit and Poster Hall Final Abstract Number: 2324 TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14 Oral Presentation: Title: Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease Session Date and Time: Wednesday, May 13, 8:30 a.m. – 9:00 a.m. EDT Session Title: mRNA &amp; Genome Editing: Technology &amp; Applications 94th European Atherosclerosis Society (EAS) Congress, May 24-27 Oral Presentation: Title: A Transformative In Vivo CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates Session Date and Time: Monday, May 25, 3:45 p.m. – 5:15 p.m. EET/9:45 a.m. – 11:15 a.m. EDT Session Title: New Pathways for Lipid and Lipoprotein Metabolism Presentation Room: Nana Hall Final Abstract Number: 159 Abstracts can be accessed on the conference websites as they become available, and the presentations will be posted on the Editas Medicine website during the conferences. About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd056YzFOQ00zTlRZM09UWTRJekl3TWpZd01qYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd056YzFOQ00zTlRZM09UWTRJekl3TWpZd01qYz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDEzMDkxNDEtMzhmNy00YTY4LTg4ODktMzQ0MDE3NjM1NTI1LTEwMzc1OTktMjAyNi0wNC0yNy1lbg==/tiny/Editas-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDEzMDkxNDEtMzhmNy00YTY4LTg4ODktMzQ0MDE3NjM1NTI1LTEwMzc1OTktMjAyNi0wNC0yNy1lbg==/tiny/Editas-Medicine-Inc-.png"/> <pre>Investor and Media Contacts:ir@editasmed.commedia@editasmed.com</pre></article></div>

EDIT

SBIO

IBBQ

LABU

Editas Medicine, Inc. announced that five abstracts have been accepted for presentation at upcoming scientific conferences, including the ASGCT 2026 Annual Meeting and the EAS Congress. The presentations will showcase new preclinical data on EDIT-401, a potential treatment for hyperlipidemia, highlighting its ability to lower LDL cholesterol through CRISPR gene editing. Key presentations include an oral presentation on the preclinical development of EDIT-401 and several poster presentations detailing pharmacokinetics and gene editing approaches. The conferences will take place from May 11 to May 27, 2026.

StockTitan

Editas Medicine

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences | EDIT Stock News